Trodelvy plus Keytruda effective for aggressive breast cancer type: Gilead Sciences Ruchika Sharma23 April 2025 10:30 AM ISTFoster City: Gilead Sciences, Inc. has announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that...
Gilead Sciences earns USFDA Breakthrough Therapy Designation for lung cancer treatment Trodelvy Ruchika Sharma19 Dec 2024 1:30 PM ISTFoster City: Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy...
Gilead Sciences Trodelvy, Keytruda combo study demonstrates promising clinical activity in first-line Metastatic Non-Small Cell Lung Cancer Ruchika Sharma12 Sept 2023 2:30 PM ISTFoster City: Gilead Sciences, Inc. has announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy...
Gilead Sciences Trodelvy under USFDA priority review for adult patients with pretreated metastatic breast cancer Ruchika Sharma14 Oct 2022 2:30 PM ISTTrodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.
Gilead Sciences cancer drug Trodelvy gets speedy USFDA approval Ruchika Sharma14 April 2021 4:11 PM ISTFoster City: Drugmaker, Gilead Sciences, has recently announced that the U.S. Food and Drug Administration (USFDA) has granted accelerated...
Gilead Sciences application for breast cancer therapy gets EMA validation Ruchika Sharma28 March 2021 11:00 AM ISTFoster City: Gilead Sciences has recently announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application...
